Alan B. Lancz & Associates, Inc. Eli Lilly & CO Transaction History
Alan B. Lancz & Associates, Inc.
- $108 Million
- Q3 2024
A detailed history of Alan B. Lancz & Associates, Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Alan B. Lancz & Associates, Inc. holds 1,730 shares of LLY stock, worth $1.39 Million. This represents 1.42% of its overall portfolio holdings.
Number of Shares
1,730
Previous 1,705
1.47%
Holding current value
$1.39 Million
Previous $1.54 Million
0.71%
% of portfolio
1.42%
Previous 1.54%
Shares
6 transactions
Others Institutions Holding LLY
# of Institutions
3,918Shares Held
765MCall Options Held
6.34MPut Options Held
7.96M-
Lilly Endowment Inc Indianapolis, IN96.9MShares$78.1 Billion0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA73.9MShares$59.5 Billion1.31% of portfolio
-
Black Rock Inc. New York, NY65.9MShares$53.1 Billion1.37% of portfolio
-
Pnc Financial Services Group, Inc. Pittsburgh, PA51.4MShares$41.4 Billion31.1% of portfolio
-
State Street Corp Boston, MA33.9MShares$27.3 Billion1.36% of portfolio
About ELI LILLY & Co
- Ticker LLY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 950,174,976
- Market Cap $766B
- Description
- Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...